This web site is a repository of publicly available information, and is not intended to form a physician-patient relationship with any individual. The content of this website is for informational purposes only. The information presented on this web site is not intended to take the place of your personal physician’s advice and is not intended to diagnose, treat, cure or prevent any disease. Discuss this information with your own physician or healthcare provider to determine what is right for you. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. The information contained herein is presented in summary form only and intended to provide broad consumer understanding and knowledge. The information should not be considered complete and should not be used in place of a visit, call, consultation or advice of your physician or other health care provider. Only a qualified physician in your state can determine if you qualify for and should undertake treatment.
Meta-analyses of placebo-controlled trials suggest that testosterone therapy in physiological doses is significantly associated with increased haematocrit, reduced high-density lipoprotein cholesterol and prostatic symptoms. 29 , 30 If prostate cancer has been excluded, there appears to be no increased risk of induction by testosterone therapy. There is inconsistent evidence regarding the risk of cardiovascular events. 29-31 A recent meta-analysis suggested increased cardiovascular risk and reported publication biases. 32 Long-term safety data are lacking, but recent reports more strongly suggest an increased risk of cardiovascular events in older men. 3 , 4 This has prompted the Endocrine Society to issue a warning statement. 5 The results and safety of long-term prospective controlled trials of testosterone therapy are awaited.